Evidence map›Paper›PMID 39137479›Full record

Observational studyESMO open2024

Bioimpedance-derived body composition parameters predict mortality and dose-limiting toxicity: the multicenter ONCO-BIVA study.

E Cereda, A Casirati, C Klersy, M Nardi, G Vandoni, E Agnello, S Crotti, S Masi, A Ferrari, P Pedrazzoli and 2 more

Abstract readMulticenter StudyObservational Study
In one paragraph

Observational study in ESMO open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Muscle Health and Prognosis in Patients With Cancer: New Insights.Journal of cachexia, sarcopenia and muscle · 2026
    Article
  4. Article
  5. Observational
  6. NutrigramFrontiers in nutrition · 2026
    Article
  7. Article
  8. Article
  9. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

E CeredaClinical Nutrition and Dietetics Unit, Fondazione IRCCS Policlinico San Matteo, Pavia.
A CasiratiClinical Nutrition and Dietetics Unit, Fondazione IRCCS Policlinico San Matteo, Pavia.
C KlersyBiostatistics & Clinical Trial Center, Fondazione IRCCS Policlinico San Matteo, Pavia.
M NardiNutritional Support Unit, Veneto Institute of Oncology IOV-IRCCS, Padua.
G VandoniClinical Nutrition, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan.
E AgnelloDietetic and Clinical Nutrition Unit, Città della Salute e della Scienza Hospital, Turin.
S CrottiClinical Nutrition and Dietetics Unit, Fondazione IRCCS Policlinico San Matteo, Pavia.
S MasiClinical Nutrition and Dietetics Unit, Fondazione IRCCS Policlinico San Matteo, Pavia.
A FerrariMedical Oncology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia.
P PedrazzoliMedical Oncology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia; Department of Internal Medicine, University of Pavia, Pavia, Italy.
R CaccialanzaClinical Nutrition and Dietetics Unit, Fondazione IRCCS Policlinico San Matteo, Pavia. Electronic address: r.caccialanza@smatteo.pv.it.
ONCO-BIVA Collaborative Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn patients with cancer, lean body mass loss is frequent and associated with worse outcomes, including reduced treatment tolerance and survival. Bioelectrical impedance analysis (BIA) is a popular method for body composition assessment. We evaluated the value of BIA-derived body composition parameters in predicting mortality and, for the first time, dose-limiting toxicity (DLT). PATIENTS AND

methodsWe conducted a prospective multicenter (n = 12) observational study in adult patients with solid neoplastic disease and receiving primary systemic treatment. We collected information on BIA-derived parameters: phase angle (PhA) <5th percentile of age and gender-specific normative values; standardized PhA (SPA) <-1.65; Nutrigram® <660 mg/24 h/m and <510 mg/24 h/m for males and females, respectively. The primary outcome and the key secondary were 1-year mortality and DLT (any-type severe toxicity requiring a delay in systemic treatment administration or a reduction of its dosage), respectively.

resultsIn total, 640 patients were included. At 12 months, death occurred in 286 patients (47.6%). All BIA-derived body composition parameters were independently associated with death: SPA, hazard ratio (HR) = 1.59 [95% confidence interval (CI) 1.30-1.95] (P < 0.001); PhA, HR = 1.38 (95% CI 1.13-1.69) (P = 0.002); Nutrigram®, HR = 1.71 (95% CI 1.42-2.04) (P < 0.001). DLT occurred in 208 patients (32.5%) and body composition parameters were associated with this outcome, particularly SPA: odds ratio = 6.37 (95% CI 2.33-17.44) (P < 0.001).

conclusionsThe study confirmed that BIA-derived body composition parameters are independently associated not only with survival but also with DLT. Although our findings were limited to patients receiving first-line systemic treatment, the evidence reported may have important practice implications for the improvement of the clinical work-up of cancer patients.

Indexed as

Body CompositionElectric ImpedanceNeoplasmsAgedAntineoplastic AgentsFemaleHumansMaleMiddle AgedProspective StudiesAntineoplastic Agentsbioelectrical impedance vectorial analysisbody compositioncancerdose-limiting toxicitymortalityphase angle

Identifiers

PMID39137479
PMCPMC11369426

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.